p300 and cyclic AMP response element-binding protein (CBP) are adenoviral E1A-binding proteins involved in multiple cellular processes, and function as transcriptional co-factors and histone acetyltransferases. Germline mutation of CBP results in Rubinstein-Taybi syndrome, which is characterized by an increased predisposition to childhood malignancies. Furthermore, somatic mutations of p300 and CBP occur in a number of malignancies. Chromosome translocations target CBP and, less commonly, p300 in acute myeloid leukemia and treatmentrelated hematological disorders. p300 mutations in solid tumors result in truncated p300 protein products or amino-acid substitutions in critical protein domains, and these are often associated with inactivation of the second allele. A mouse model confirms that p300 and CBP function as suppressors of hematological tumor formation. The involvement of these proteins in critical tumorigenic pathways (including TGF-b, p53 and Rb) provides a mechanistic route as to how their inactivation could result in cancer.
Introduction p300 was originally identified using protein-interaction assays with the adenoviral E1A oncoprotein (Eckner et al., 1994) . p300 has been implicated in a number of diverse biological functions including proliferation, cell cycle regulation, apoptosis, differentiation and DNA damage response (Giles et al., 1998; Giordano and Avantaggiati, 1999; Goodman and Smolik, 2000; ). p300 is highly homologous to the cyclic AMP response element-binding (CREB) protein (CBP), with 63% homology at the amino-acid level. The two proteins have a number of common roles in physiological processes, although it is increasingly clear that they serve several distinct, non-overlapping functions. Both p300 and CBP are evolutionarily conserved in metazoans as diverse as mouse, Xenopus, Drosophila and C. elegans, although in lower organisms there is a single orthologue. p300/CBP function primarily as transcription cofactors for a number of nuclear proteins. These include known oncoproteins (such as myb, jun, fos), transforming viral proteins (such as E1A, E6 and large T antigen) and tumor-suppressor proteins (such as p53, E2F, Rb, Smads, RUNX and BRCA1) (Eckner et al., 1994; Avantaggiati et al., 1997; Lill et al., 1997; Pouponnot et al., 1998; Patel et al., 1999; Ghosh et al., 2000; Martinez-Balbas et al., 2000; Marzio et al., 2000; Pao et al., 2000; Tomita et al., 2000; . Transcriptional coactivation is mediated by p300/CBP acting as a bridge linking DNA-binding transcription factors to the basal transcriptional machinery. In addition, the surface of these molecules works as a scaffold for the nucleation of various transcription factors involved in complex cellular responses. The classical model of p300/CBP as a scaffold is based on experiments performed on the b-interferon gene promoter in response to viral infection Munshi et al., 1998) . Upon stimulation, the b-interferon enhanceosome is assembled on the surface of the p300 molecule, bringing together transcription factors such as NF-kB, IRF1, ATF2/c-Jun and the architectural protein HMG I(Y) to the b-interferon gene promoter. The role of p300 in this response is critical, as it brings about the assembly of specific nuclear factors and the RNA polymerase holoenzyme to execute a rapid, but brief, transcriptional activation of the b-interferon gene.
In 1996, two independent groups confirmed that p300 and CBP function as histone acetyltransferases (HATs) (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) . Unlike other HATs, which have limited substrate specificity for histones, p300 and CBP are capable of acetylating all the four histones in vitro and probably in vivo. Acetylation of specific lysine residues on histone tails is believed to neutralize the negative charge, reducing the tight interaction between histones and the DNA molecule. Histone acetylation has long been associated with genes that are actively transcribed (Allfrey et al., 1964) . Therefore, p300 and CBP appear to couple transcription factor recognition to chromatin remodelling. It is now known that the coordination of gene transcription is controlled by a variety of histone modifications including acetylation, phosphorylation, methylation and ubiquitination. The complex combination of these modifications constitutes the 'histone code', which mediates the activation and repression of specific gene transcription (Strahl and Allis, 2000) . p300 and CBP are also capable of acetylating a number of non-histone proteins, including p53, p73, Rb, E2F, myb, myoD, HMG(I)Y, GATA1 and a-importin (Gu and Roeder, 1997; Boyes et al., 1998; Munshi et al., 1998; Sakaguchi et al., 1998; Bannister et al., 2000; Martinez-Balbas et al., 2000; Marzio et al., 2000; Tomita et al., 2000; Polesskaya and Harel-Bellan, 2001; Costanzo et al., 2002) . This has led to the suggestion that acetylation of nonhistone proteins is an important post-translation modification, analogous to phosphorylation (Kouzarides, 2000) . Like phosphorylation, acetylation of proteins can affect a number of different pathways. Acetylation of sequence-specific DNA-binding nuclear proteins such as p53, p73, Rb and E2F (on lysine residues adjacent to DNA-binding domains) augments promoter binding, resulting in activation of transcriptional activity. In contrast, acetylation of HMG(I)Y on lysine residues within the DNAbinding domain reduces transcriptional activity. Acetylation also affects protein-protein interactions as in the case of Rb and mdm2, and may be involved in nuclear import and microtubule assembly (Takemura et al., 1992) . p300 and CBP have been implicated in embryonic development and cancer. The role of p300 as a putative tumor-suppressor gene has been suspected since its identification as an E1A-binding protein. In this review, we summarize the evidence for the potential role of p300 and CBP in cancer. While the published data often fail to distinguish between p300 and CBP, analysis of chromosome translocations in hematological malignancies and mutations in solid tumors suggest a fundamental difference in the involvement of these homologues in cancer. Furthermore, a number of experiments have also suggested differences in mechanisms by which the two proteins may affect tumor formation.
Germline mutations: Rubinstein-Taybi syndrome
Rubinstein-Taybi syndrome (RTS) is a developmental disorder caused by heterozygous germline mutations (point mutations, translocations or deletions) of the CBP gene (Petrij et al., 1995 (Petrij et al., , 2000 Rubinstein, 1990) . RTS is characterized by broad thumbs, cranio-facial and cardiac abnormalities, as well as mental retardation. Patients with RTS have an increased predisposition to cancer, usually childhood tumors of neural crest origin (an approximate incidence of 5%) (Miller and Rubinstein, 1995) . However, it has not been determined if the remaining CBP allele is somatically mutated/inactivated in these tumors. To date, no syndrome involving the germline mutation of the p300 gene has been described.
Somatic mutations: p300 and CBP translocations in leukemia/lymphoma
The earliest observations linking p300 and CBP to cancer were studies in leukemias, where chromosome translocations disrupt the CBP gene. The first to be characterized was the t(8,16)(p11,p13) translocation associated with the M4/M5 subtype of acute myeloid leukemia (AML) (Borrow et al., 1996; Giles et al., 1997a; Panagopoulos et al., 2001 ). This translocation fuses the gene encoding the monocytic leukemia zincfinger protein (MOZ) with the amino terminus of CBP. The t(8,16) translocation is rare, accounting for only four in 1000 patients with AML. An even rarer variant has been described, t(8,22)(p11,q13), which fuses MOZ to p300 (Lai et al., 1985; Chaffanet et al., 2000; Kitabayashi et al., 2001b) . MLL-CBP and MLL-p300 translocations (MLL-mixed lineage leukemia) have also been described in treatment-related hematological disorders (Ida et al., 1997; Rowley et al., 1997; Satake et al., 1997; Sobulo et al., 1997; Taki et al., 1997) . While the MOZ-CBP translocation may result in activation of the HAT domain in the fusion protein, loss of the amino terminus, which is a common event in all known translocations, may be important for cellular transformation (Champagne et al., 2001; Kitabayashi et al., 2001a) . Chromosomal rearrangements involve CBP more commonly than p300. As most of the CBP rearrangements target the same 13 kb genomic interval, it is thought that the presence of an unstable genomic element in this region may account for the higher frequency (Giles et al., 1997b) .
Somatic mutations: p300 and CBP in solid tumors
In solid tumors, loss of heterozygosity (LOH) studies have identified the long arm of chromosome 22 as a frequent target of allelic imbalance in a variety of malignancies including colorectal, breast, ovarian, hepatocellular and oral carcinomas, meningiomas, schwannomas and phaeochromocytomas (Chen et al., 1992; Shin et al., 1993; Takahashi et al., 1993; Englefield et al., 1994; Ruttledge et al., 1994; Twist et al., 1994; Bryan et al., 1996; Duriez et al., 1997; Allione et al., 1998; Miyakawa et al., 1998) . Inactivation of the NF2 gene on 22q12 probably accounts for the allelic loss seen in tumors of neural crest origin. However, the search for a tumor-suppressor gene on 22q in the colon, breast, ovarian and hepatocellular carcinomas prompted mutational analyses of other genes in the region. The first of these studies on the p300 gene (located on 22q13) was performed on 27 primary colon adenocarcinomas and two primary gastric adenocarcinomas (Muraoka et al., 1996) . Two missense point mutations were uncovered, one in each tumor type. These somatic mutations resulted in amino-acid substitutions at conserved residues in critical domains on the p300 protein (colorectal carcinoma -HAT domain, and gastric carcinoma -cysteine-histidine-rich domain 2), and were both associated with loss of the wild-type allele. The analysis was extended in our laboratory to include a total of 222 cancer samples (Gayther et al., 2000; Ozdag et al., 2002) . Truncating mutations were seen in six out of 107 (5.6%) cell lines and two out of 115 (1.7%) primary tumors. The resultant truncated proteins had loss of important domains, and were associated with loss or silencing of the second allele, therefore suggestive of a classical tumor-suppressor 'two-hit' inactivation. Further mutations in cell lines and primary tumor samples have been described, but appear to be uncommon (Ohshima et Bryan et al., 2002; Suganuma et al., 2002) . The data on the frequency of mutations are summarized in Table 1 . Table 2 contains a description of all mutations described to date. CBP mutations are even rarer: only two heterozygous truncations were detected in cell lines, and no other mutations seen in 63 cancer cell lines and 116 primary tumors (Ozdag et al., 2002) .
A recent study was carried out to identify LOH at the 22q13 p300 locus and 16p13 CBP locus (Tillinghast et al., 2003) . Screening a panel of 103 cell lines showed LOH of 51% at the p300 locus and 35% at the CBP locus. Concordant loss at both loci occurred in 19% of cell lines, but this was not a statistically significant event. Expression levels of p300 and CBP were not determined, so these results suggest that haploinsufficiency resulting from loss of one paralogue is sufficient for tumor progression. Western blots of whole-cell lysates (using p300 N-terminal antibody) and mutational analyses of limited regions were performed in selected samples. However, these analyses failed to identify the previously described p300 mutations in cell lines HCT15, HT29, OVCAR8 and MDA-435. We decided not to include this study in the tables, which are only based on analyses where the whole gene was screened.
A cell line with mutation of both p300 alleles HCT116 is a near-diploid colorectal carcinoma cell line in which we initially described a heterozygous truncating mutation of p300 at the DNA level on exon 31 (nucleotide 6294 delA), associated with no expression of the second allele at the RNA level. The mutation results in the monoallelic expression of a p300 protein truncated downstream of the HAT domain. Subsequently, a second frameshift mutation on exon 27 (nucleotide 5601 delA) was described in the DNA of this cell line (Bryan et al., 2002) . This mutation would be predicted to truncate the protein within the HAT domain. We have recently confirmed that only the allele with a mutation on exon 31 is expressed, while the second mutation on exon 27 occurs in the second allele and is not expressed. These results suggest that RNA transcribed from the allele with the exon 27 mutation is degraded by nonsense-mediated mRNA degradation (NMRD). This is a known phenomenon in cells with biallelic truncating mutations at different sites, where transcripts from the allele with a mutation upstream (i.e. 5 0 ) are preferentially degraded (Cao and Parker, 2003) . The interest in this cell line resides in that the truncated p300 has intact acetyltransferase activity seen in in vitro histone acetylation assays and normal p53 acetylation in response to DNA damage (Sakaguchi et al., 1998; Gayther et al., 2000) .
There are other cell lines with biallelic p300 mutations at the DNA level. In HOC313 (oral squamous cell carcinoma cell line), mutations were detected on nucleotides 6540 and 6822. Only the allele with a mutation in nucleotide 6822 (i.e. the 3 0 mutation) is expressed (Suganuma et al., 2002) . In another example, LIM2405 (colorectal carcinoma cell line), frameshift mutations were identified in nucleotides 3929 and 5601. Both alleles are not expressed in this cell line (Bryan et al., 2002) .
Mutations of other HATs -p/CAF
Mutational analyses of p/CAF (p300/CBP-associated factor), a HAT homologous to Gcn5, have also been performed (Nishimori et al., 2000; Ozdag et al., 2002) . Only missense variants were identified, with no truncating or loss of function mutations. Mutation types: fs -frameshift, non -nonsense, mis -missense, ifd -in-frame deletion, ifi -in-frame insertion, spl -splice-site alteration resulting in frameshift, (trunc) -mutation that results in a truncated p300 protein p300/CBP and cancer NG Iyer et al p300 and CBP -tumor-suppressor genes?
Since mutations are uncommon, doubts remain that p300/CBP function as classical tumor-suppressor genes.
Transgenic mouse models can be important in establishing the pathogenic role of specific gene inactivation in cancer. CBP and p300 knockouts (homozygous null, À/À) are early embryonic lethal (Yao et al., 1998; Oike Mutation types: fs -frameshift, non -nonsense, mis -missense, ifd -in-frame deletion, ifi -in-frame insertion, spl -splice-site alteration resulting in frameshift. p300 domains: CH1, CH2, CH3 -cysteine-histidine-rich domains 1, 2 and 3, respectively; KIX -kinase-inducible binding domain; bromo -bromodomain, N-term, C-term -N and C terminals, respectively, HAT -histone acetyltransferase domain. Second allele status: hemi -hemizygous (only one expressed transcript), loss -of second allele, ? -unknown, wt -wild type, allele 1, allele 2 -different alleles, homo -homozygous mutation p300/CBP and cancer NG Iyer et al et al., 1999a, b) . Double heterozygotes and a significant fraction of p300 heterozygotes also do not survive embryogenesis, confirming that the presence of one homologue is insufficient to compensate for loss of the other. CBP heterozygotes developed multiple phenotypic abnormalities (similar to RTS), hematopoeitic failure and, eventually, hematological malignancies (Oike et al., 1999a; Kung et al., 2000) . Importantly, in these malignancies, there was somatic inactivation of the second CBP allele, confirming that, at least in the mouse, CBP functions as a classical tumor-suppressor gene. The effect of complete inactivation of p300 and CBP has recently been assessed using chimeric mice (Rebel et al., 2002) . Embryonic stem cells null for p300 and CBP were generated and injected into blastocysts of different mice strains to obtain p300 and CBP null chimeras. Both CBP and p300 chimeras developed hematological malignancies (thymic lymphoma and histiocytic sarcomas, respectively). These tumors were only composed of cells null for the respective protein, confirming that both CBP and p300 appear to play a role in suppressing hematologic tumor development. As p300 was identified as an adenoviral E1A-binding protein, experiments on the transforming ability of E1A revealed that interaction with p300 is required to induce S-phase entry, override contact inhibition and block major differentiation pathways (Eckner et al., 1994; Smits et al., 1996; Yang et al., 1996) . Furthermore, E1A proteins from oncogenic and nononcogenic adenoviruses differ in their mechanisms of binding p300 (Lipinski et al., 1999) . Both the papillomavirus E6 protein and SV40 large T antigen require interaction with p300 for cellullar transformation and dysregulation of the p53 pathway (Eckner et al., 1996; Patel et al., 1999; Zimmermann et al., 1999) . p300 is a key cofactor in the proper functioning of other tumor-suppressor proteins. Critical pathways such as the TGF-b, p53 and Rb-E2F pathways require p300 cofactor activation to mediate the transcription of target genes.
Smads and RUNX cooperate with p300 to trigger transcription of target genes in response to TGF-b activation and signalling (Pouponnot et al., 1998; Ghosh et al., 2000) . The involvement of this pathway is not only intriguing but also highlight the possible mechanisms to explain the tumor-suppressor role of p300. TGF-b, Smad2, Smad 4 and RUNX have all been shown to function as suppressors of tumor formation in mouse knockout models, and appear to be inactivated in a number of malignancies (reviewed in Ito and Miyazono, 2003) . The role of p300 in the TGF-b pathway has been established in a recent study (Suganuma et al., 2002) . Transfection of full-length, wild-type p300 in cell lines with truncating p300 mutations resulted in reduction of proliferative capacity in these cells. Growth suppression was achieved by activation of TGF-b-dependent transcriptional activity, suggesting that deregulation of this signalling pathway may present a mechanism by which p300 mediates its tumor-suppressing ability. Transfection of CBP in the same cell lines was unable to suppress growth under identical conditions, suggesting the specificity of the p300 effect. p300/CBP modulate the p53 pathway at multiple levels (reviewed in Grossman, 2001) . p300 contributes to maintaining p53 stability by regulating its ubiquitination and degradation, through both mdm2-dependent andindependent mechanisms (Grossman et al., 1998 (Grossman et al., , 2003 Kawai et al., 2001) . After DNA damage, p53 is activated by phosphorylation by various kinases and acetylation at specific amino-acid residues by p300/CBP (Sakaguchi et al., 1998) . p53 acetylation is thought to promote target gene activation by increasing the stability of the p53-p300-DNA complex (Gu and Roeder, 1997; Dornan et al., 2003) . Furthermore, p300 is required for p53-mediated transactivation of target genes through its coactivator function and acetylation of target gene histones (Avantaggiati et al., 1997; Lill et al., 1997; Barlev et al., 2001; Espinosa and Emerson, 2001 ). Loss of p300 could disrupt p53 activation, stability, transactivation of target genes and alter the cell fate in response to p53 activation. In fact, p300 knockdown by hammerhead ribozymes inhibits apoptosis, probably by disrupting the p53-mediated response to DNA damage (Yuan et al., 1999a, b) .
Despite all the evidence presented above, results from a number of experiments appear to question the tumorsuppressor function of p300 and CBP. For example, fibroblasts obtained from p300 and CBP null embryos have significant proliferation defects, and cannot be maintained in culture as cells uniformly progress to senescence (Yao et al., 1998; Oike et al., 1999a, b) . Similarly, when p300 and CBP are knocked down using hammerhead ribozymes, resultant cells have markedly reduced proliferative capacity (Yuan et al., 1999a) . Experiments on human melanocyte cultures suggest that reduction of p300 levels precede the activation of senescent checkpoints (Bandyopadhyay et al., 2002) . p300 and CBP are also required for maintaining cells in cycle, as microinjecting antibodies against p300/CBP inhibit the S-phase entry and result in G1/S arrest (AitSi-Ali et al., 2000).
Conclusion
On balance, the evidence appears to weigh in favor of both p300 and CBP playing a role in tumorigenesis. p300 truncating mutations in solid tumors are rare, but do occur, and are associated with loss of the second allele. In hematological malignancies, translocations more commonly target CBP, probably due to the presence of an unstable genomic element within the 5 0 end of the gene. Recent data from our laboratory show that a proportion of breast and colorectal carcinomas express p300 at extremely low levels (H Ozdag and C Caldas -unpublished observations). The significance of these findings is supported by its tissue specificity, as bladder, renal and ovarian tumors do not appear to have significant expression abnormalities. Moreover, it is clear that both p300 and CBP function as tumor suppressors in mice, where deficiency results in the development of hematological malignancies. The role of p300 in pathways critical in tumorigenesis (p53, Rb-E2F or TGF-b) could be a mechanism by which p300 contributes to cancer formation.
